ORAL GANCICLOVIR DOSING IN TRANSPLANT RECIPIENTS AND DIALYSIS PATIENTS BASED ON RENAL FUNCTION1
Mark D. Pescovitz, Donald Jung(Anshan Hospital), K. Wicker, Bonnie Brook, T. Pruett, Charles A. Robinson(Center for Global Development), Thomas A. Gonwa(Jacksonville College), R. McGory, Kay Griffy(Roche (Switzerland))
Cited by 46
Related Papers
Sjögren's syndrome. Proposed criteria for classification
|Arthritis & Rheumatism|1986|685
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
|The Lancet|1997|501
Oral Ganciclovir for Patients with Cytomegalovirus Retinitis Treated with a Ganciclovir Implant
|New England Journal of Medicine|1999|485
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
|New England Journal of Medicine|2002|394
Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
|Antimicrobial Agents and Chemotherapy|2000|363